Overview
NICE is unable to make a recommendation on enfortumab vedotin (Padcev) for previously treated locally advanced or metastatic urothelial cancer. This is because Astellas did not provide an evidence submission.
Last reviewed: 15 June 2022
Next review: We will review this decision if the company decides to make a submission.